Patient assistance programs will be available
The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)
The table shows general patterns, but your individual response may differ significantly
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing
Instead of asking whether GLP-1 medications work, clinicians are beginning to ask for whom they work best and what alternative pathways should be considered when responses are incomplete. We asked our experts to explain why GLP-1s dont always work for weight loss and what alternatives are available
For compounded semaglutide specifically, treatment duration considerations are similar, but access and cost dynamics differ